UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
________________________________
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of
Report (Date of earliest event reported): August 3, 2021
|
SANARA MEDTECH INC.
|
|
(Exact
name of registrant as specified in its charter)
|
|
Texas
|
|
001-39678
|
|
59-2219994
|
|
(State
or other jurisdiction of
|
|
(Commission File
Number)
|
|
(IRS
Employer
|
|
incorporation)
|
|
|
|
Identification
No.)
|
|
|
|
|
|
|
|
1200 Summit Avenue, Suite 414
Fort Worth, Texas
|
|
76102
|
|
(Address
of principal executive offices)
|
|
(Zip
Code)
|
Registrant’s
telephone number, including area code: (817) 529-2300
(Former
name or former address, if changed since last report)
Not Applicable
Check
the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2.
below):
|
☐
|
Written
communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
|
|
☐
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
|
☐
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2(b))
|
|
☐
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4(c))
|
Securities
registered pursuant to Section 12(b) of the Act:
|
Title of each class
|
|
Trading Symbol(s)
|
|
Name of each exchange on which registered
|
|
Common
Stock, $0.001 par value
|
|
SMTI
|
|
The
Nasdaq Capital Market
|
Indicate
by check mark whether the registrant is an emerging growth company
as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of
1934 (§240.12b-2 of this chapter).
Emerging growth
company
☐
If an
emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange Act. ☐
Item
5.08 Shareholder Director Nominations
To the
extent applicable, the information in Item 8.01 of this Current
Report on Form 8-K is incorporated by reference into this Item
5.08.
Item
8.01 Other Events
On
August 3, 2021, the board of directors (the “Board”) of
Sanara MedTech Inc. (the “Company”) established
September 30, 2021 as the date of the Company’s 2021 annual
meeting of shareholders (the “2021 Annual Meeting”) and
set August 16, 2021 as the record date for determining shareholders
who are eligible to receive notice of and vote at the 2021 Annual
Meeting. The date of the 2021 Annual Meeting represents a change of
more than 30 calendar days from the anniversary of the date deemed
to be the date of the preceding year’s annual meeting
pursuant to Rule 14a-4(c) of the Securities Exchange Act of 1934,
as amended (the “Exchange Act”). The Company will
publish additional details regarding the exact time, location and
matters to be voted on at the 2021 Annual Meeting in the
Company’s proxy statement for the 2021 Annual
Meeting.
In
order for shareholder proposals to be presented at the 2021 Annual
Meeting, including by means of inclusion of a shareholder proposal
in the proxy materials under Rule 14a-8 of the Exchange Act, the
Company must receive proper notice at the Company’s principal
executive offices not later than the close of business on August
16, 2021, which the Company has determined to be a reasonable time
before it expects to begin to print and distribute its proxy
materials prior to the 2021 Annual Meeting. Any such proposal must
also meet the requirements set forth in the rules and regulations
of the Securities and Exchange Commission in order to be eligible
for inclusion in the proxy materials for the 2021 Annual Meeting.
The August 16, 2021 deadline will also apply in determining whether
notice of a shareholder proposal is timely for purposes of
exercising discretionary voting authority with respect to proxies
under Rule 14a-4(c) of the Exchange Act.
All
proposals must be addressed to the Corporate Secretary at
“Sanara MedTech Inc., 1200 Summit Avenue, Suite 414, Fort
Worth, TX 76102, Attention: Corporate
Secretary.”
SIGNATURES
Pursuant to the
requirements of the Securities Exchange Act of 1934, the registrant
has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
|
|
Sanara MedTech Inc.
|
|
|
|
|
|
|
|
|
Date: August
6, 2021
|
By:
|
/s/ Michael D.
McNeil
|
|
|
|
Name:
|
Michael D.
McNeil
|
|
|
|
Title:
|
Chief Financial
Officer
|
|